What is the forward PE ratio for Charles River Laboratories International, Inc. (CRL)?

The forward PE ratio for CRL stock is 26.08.

Charles River Laboratories International (CRL) Forward PE Ratio: History & Chart

Compare

Charles River Laboratories International, Inc.(CRL)

Medical - Diagnostics & Research · Wilmington, MA

$295.19+3.74 (+1.28%)

At close: Aug 21, 2026, 4:00 PM ET

Compare

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA

19,000 employees

www.criver.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Birgit Girshick

View full financials

NAME	MARKET CAP	FORWARD PE RATIO
Charles River Laboratories International, Inc. (CRL)	$14.22B	26.08
Revvity, Inc. (RVTY)vs ›	$13.92B	23.29
Baxter International Inc. (BAX)vs ›	$13.62B	12.83
Exelixis, Inc. (EXEL)vs ›	$13.59B	18.14
The Cooper Companies, Inc. (COO)vs ›	$14.87B	16.46
Solventum Corporation (SOLV)vs ›	$15.51B	12.51
Tempus AI, Inc. (TEM)vs ›	$12.74B	N/A
Align Technology, Inc. (ALGN)vs ›	$11.64B	14.40
Bio-Techne Corporation (TECH)vs ›	$11.32B	37.61
DaVita Inc. (DVA)vs ›	$11.16B	11.71

NAME

MARKET CAP

FORWARD PE RATIO

Charles River Laboratories International, Inc. (CRL)

$14.22B

26.08

Revvity, Inc. (RVTY)vs ›

$13.92B

23.29

Baxter International Inc. (BAX)vs ›

$13.62B

12.83

Exelixis, Inc. (EXEL)vs ›

$13.59B

18.14

The Cooper Companies, Inc. (COO)vs ›

$14.87B

16.46

Solventum Corporation (SOLV)vs ›

$15.51B

12.51

Tempus AI, Inc. (TEM)vs ›

$12.74B

N/A

Align Technology, Inc. (ALGN)vs ›

$11.64B

14.40

Bio-Techne Corporation (TECH)vs ›

$11.32B

37.61

DaVita Inc. (DVA)vs ›

$11.16B

11.71

Fiscal year end	Consensus EPS	Estimate range	Analysts	Implied P/E
2026-12-27	$11.32	$10.95 – $11.48	10	26.1x
2027-12-27	$12.73	$12.07 – $13.19	10	23.2x
2028-12-27	$14.15	$8.82 – $17.85	5	20.9x

Fiscal year end

Consensus EPS

Estimate range

Analysts

Implied P/E

2026-12-27

$11.32

$10.95 – $11.48

26.1x

2027-12-27

$12.73

$12.07 – $13.19

23.2x

2028-12-27

$14.15

$8.82 – $17.85

20.9x

Forward PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Forward PE Ratio: 26.08

CRL Forward PE Ratio Metrics

CRL Competitors' Forward PE Ratio

Trailing vs Forward

Forward P/E by Fiscal Year

Forward PE Ratio Formula & Definition

Forward PE Ratio FAQ

Related Metrics